APTK.ME
Public Joint-Stock Company Pharmacy Chain 36.6 [APTK.ME] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
APTK.ME Stock Summary
Top APTK.ME Correlated Resources
APTK.ME
Top 10 Correlated ETFs
APTK.ME
Top 10 Correlated Stocks
APTK.ME
APTK.ME Financial details
Company Rating
Neutral
Market Cap
95.35B
Income
-7.37B
Revenue
85.3B
Book val./share
-0.75
Cash/share
0.13
Dividend
-
Dividend %
-
Employees
12.7K
Optionable
No
Shortable
Yes
Earnings
27 Apr 2021
P/E
-12.93
Forward P/E
-
PEG
1.39
P/S
1.12
P/B
-13.63
P/C
96.12
P/FCF
-96.8
Quick Ratio
0.11
Current Ratio
0.7
Debt / Equity
-6.2
LT Debt / Equity
-3.74
-
-
EPS (TTM)
-0.12
EPS next Y
-
EPS next Q
-
EPS this Y
-150.97%
EPS next Y
-
EPS next 5Y
4660.55%
EPS last 5Y
NAN%
Revenue last 5Y
-3.09%
Revenue Q/Q
63.15%
EPS Q/Q
-114.91%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-21%
ROE
47%
ROC
-
Gross Margin
20%
Oper. Margin
-
Profit Margin
-9%
Payout
-
Shs Outstand
7.63B
Shs Float
7.63B
-
-
-
-
Target Price
-
52W Range
8.394-15.3
52W High
-16.69%
52W Low
+56.2%
RSI
38
Rel Volume
-
Avg Volume
-
Volume
63.61K
Perf Week
5.77%
Perf Month
2.41%
Perf Quarter
2.76%
Perf Half Y
2.43%
-
-
-
-
Beta
0.34017
-
-
Volatility
0.26%, 0.2%
Prev Close
7.58%
Price
12.496
Change
7.58%
APTK.ME Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 40.09 | 18.31 | 18.8 | 9.25 | 5.77 | |
| Net income per share | -8.15 | -4.97 | -9.67 | -1.78 | 0.93 | |
| Operating cash flow per share | -3.04 | -4.22 | -3.87 | -0.36 | -0.49 | |
| Free cash flow per share | -3.43 | -4.4 | -4.22 | -0.76 | -0.78 | |
| Cash per share | 0.51 | 0.25 | 0.21 | 0.17 | 0.15 | |
| Book value per share | -0.46 | -5.24 | -15.49 | -4.73 | -0.84 | |
| Tangible book value per share | -26.58 | -13.95 | -20.26 | -6.67 | -2.67 | |
| Share holders equity per share | -0.46 | -5.24 | -15.49 | -4.73 | -0.84 | |
| Interest debt per share | 19.89 | 13.55 | 25.94 | 9.22 | 7.98 | |
| Market cap | 10.49B | 20.05B | 11.76B | 65.2B | 91.55B | |
| Enterprise value | 30.2B | 51.57B | 66.49B | 104.95B | 140.26B | |
| P/E ratio | -1.12 | -1.53 | -0.51 | -7.36 | 14.41 | |
| Price to sales ratio | 0.23 | 0.42 | 0.26 | 1.42 | 2.33 | |
| POCF ratio | -3.01 | -1.8 | -1.28 | -36.53 | -27.2 | |
| PFCF ratio | -2.67 | -1.73 | -1.17 | -17.14 | -17.31 | |
| P/B Ratio | -19.75 | -1.45 | -0.32 | -2.77 | -16.05 | |
| PTB ratio | -19.75 | -1.45 | -0.32 | -2.77 | -16.05 | |
| EV to sales | 0.66 | 1.07 | 1.49 | 2.28 | 3.57 | |
| Enterprise value over EBITDA | -5.16 | -6.35 | -6.11 | 60.88 | 8.41 | |
| EV to operating cash flow | -8.67 | -4.63 | -7.23 | -58.8 | -41.67 | |
| EV to free cash flow | -7.69 | -4.45 | -6.64 | -27.58 | -26.52 | |
| Earnings yield | -0.89 | -0.65 | -1.95 | -0.14 | 0.07 | |
| Free cash flow yield | -0.37 | -0.58 | -0.85 | -0.06 | -0.06 | |
| Debt to equity | -32.26 | -2.05 | -0.88 | -1.26 | -6.2 | |
| Debt to assets | 1.01 | 1.35 | 2.12 | 1.72 | 1.1 | |
| Net debt to EBITDA | -3.37 | -3.88 | -5.03 | 23.06 | 2.92 | |
| Current ratio | 0.47 | 0.63 | 0.3 | 0.54 | 1.23 | |
| Interest coverage | -1.02 | -1.04 | -0.54 | -0.13 | 0.23 | |
| Income quality | 0.37 | 0.85 | 0.4 | 0.2 | -0.53 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.67 | 0.57 | 0.35 | 0.3 | 0.23 | |
| Capex to operating cash flow | 0.13 | 0.04 | 0.09 | 1.13 | 0.57 | |
| Capex to revenue | -0.01 | -0.01 | -0.02 | -0.04 | -0.05 | |
| Capex to depreciation | -0.43 | -0.31 | -0.15 | -0.39 | -0.36 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.22 | 24.21 | 58.06 | 13.76 | 4.19 | |
| ROIC | -0.15 | -0.25 | 0.85 | -0.1 | 0.03 | |
| Return on tangible assets | -0.63 | -0.77 | -1.07 | -0.39 | 0.15 | |
| Graham Net | -35.91 | -18.67 | -27.6 | -10.35 | -8.3 | |
| Working capital | -14.76B | -9.37B | -25.74B | -11.99B | 5.76B | |
| Tangible asset value | -30.46B | -36.76B | -48.15B | -33.19B | -18.2B | |
| Net current asset value | -32.16B | -37.97B | -58.47B | -41.95B | -29.8B | |
| Invested capital | -38.21 | -2.33 | -1.5 | -1.72 | -8.72 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 17.3B | 15.66B | 12.17B | 13.06B | 10.57B | |
| Average inventory | 7.33B | 7.65B | 7.22B | 7.55B | 6.39B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 223.41 | 185.53 | 123.4 | 144.74 | 114.66 | |
| Days of inventory on hand | 73.69 | 78.71 | 75.53 | 83.65 | 74.31 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.63 | 1.97 | 2.96 | 2.52 | 3.18 | |
| Inventory turnover | 4.95 | 4.64 | 4.83 | 4.36 | 4.91 | |
| ROE | 17.6 | 0.95 | 0.62 | 0.38 | -1.11 | |
| Capex per share | -0.39 | -0.17 | -0.35 | -0.41 | -0.28 |
Quarterly Fundamentals Overview
Last date of statement is 2020-12-31 for Q4
| Metric | History | 2013-06-30 | 2019-06-30 | 2019-12-31 | 2020-06-30 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 35.39 | 3.68 | 3.87 | 1.67 | 2.73 | |
| Net income per share | -6.59 | -0.74 | -0.35 | 0.18 | -0.17 | |
| Operating cash flow per share | 6.89 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | -2.44 | 0 | 0 | 0 | 0 | |
| Cash per share | 5.82 | 0.06 | 0.12 | 0.17 | 0.13 | |
| Book value per share | -7.2 | -2.7 | -3.44 | -3.4 | -0.75 | |
| Tangible book value per share | -23.77 | -4.33 | -4.85 | -4.65 | -2.39 | |
| Share holders equity per share | -7.2 | -2.7 | -3.44 | -3.4 | -0.75 | |
| Interest debt per share | 102.53 | 6.04 | 6.35 | 6.95 | 6.79 | |
| Market cap | 2.34B | 77.85B | 84.08B | 107.02B | 107.2B | |
| Enterprise value | 13.78B | 116.23B | 123.83B | 156.37B | 155.91B | |
| P/E ratio | -0.72 | -3.82 | -8.83 | 19.26 | -20.76 | |
| Price to sales ratio | 0.53 | 3.09 | 3.17 | 8.38 | 5.14 | |
| POCF ratio | 2.74 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -7.77 | 0 | 0 | 0 | 0 | |
| P/B Ratio | -2.63 | -4.22 | -3.57 | -4.13 | -18.79 | |
| PTB ratio | -2.63 | -4.22 | -3.57 | -4.13 | -18.79 | |
| EV to sales | 3.15 | 4.61 | 4.67 | 12.24 | 7.48 | |
| Enterprise value over EBITDA | -74.07 | -47.42 | 178.94 | 38.94 | 185.83 | |
| EV to operating cash flow | 16.17 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -45.77 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.35 | -0.07 | -0.03 | 0.01 | -0.01 | |
| Free cash flow yield | -0.13 | 0 | 0 | 0 | 0 | |
| Debt to equity | -6.01 | -1.36 | -1.26 | -1.55 | -6.2 | |
| Debt to assets | 0.88 | 1.55 | 1.72 | 1.72 | 1.1 | |
| Net debt to EBITDA | -61.51 | -15.66 | 57.45 | 12.29 | 58.06 | |
| Current ratio | 0.85 | 0.47 | 0.54 | 0.76 | 1.23 | |
| Interest coverage | -0.4 | 0 | 0 | 0 | 0 | |
| Income quality | -1.05 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.47 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.26 | 0.33 | 0.3 | 0.27 | 0.23 | |
| Capex to operating cash flow | -1.35 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.26 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -12.96 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 32.68 | 6.72 | 5.19 | 3.73 | 1.69 | |
| ROIC | -0.02 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | -0.05 | -0.23 | -0.1 | 0.05 | -0.03 | |
| Graham Net | -140.67 | -7 | -7.54 | -7.41 | -7.41 | |
| Working capital | -2.14B | -14.01B | -11.99B | -5.13B | 5.76B | |
| Tangible asset value | -2.94B | -29.63B | -33.19B | -35.46B | -18.2B | |
| Net current asset value | -7.75B | -39.55B | -41.95B | -45.54B | -29.8B | |
| Invested capital | -13.66 | -2.1 | -1.72 | -1.95 | -8.72 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 7.03B | 9.25B | 10.57B | 8.37B | 8.07B | |
| Average inventory | 4.01B | 6.18B | 6.39B | 6.49B | 5.23B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 213.7 | 45.43 | 56.18 | 79.7 | 43.95 | |
| Days of inventory on hand | 99.59 | 31.08 | 32.47 | 71.23 | 28.48 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.42 | 1.98 | 1.6 | 1.13 | 2.05 | |
| Inventory turnover | 0.9 | 2.9 | 2.77 | 1.26 | 3.16 | |
| ROE | 0.92 | 0.28 | 0.1 | -0.05 | 0.23 | |
| Capex per share | -9.33 | 0 | 0 | 0 | 0 |
APTK.ME Frequently Asked Questions
What is Public Joint-Stock Company Pharmacy Chain 36.6 stock symbol ?
Public Joint-Stock Company Pharmacy Chain 36.6 is a RU stock , located in Moscow of Moscow and trading under the symbol APTK.ME
What is Public Joint-Stock Company Pharmacy Chain 36.6 stock quote today ?
Public Joint-Stock Company Pharmacy Chain 36.6 stock price is $12.496 today.
Is Public Joint-Stock Company Pharmacy Chain 36.6 stock public?
Yes, Public Joint-Stock Company Pharmacy Chain 36.6 is a publicly traded company.
Company Profile
- Market Capitalization 95.35B
- Employee 12.7K
- Headquarters MOSCOW,MOSCOW,RU
- IPO Date 2005-01-20
-
Website
https://pharmacychain366.ru 
Public Joint-Stock Company Pharmacy Chain 36.6 operates pharmacies in Russia. Its pharmacies offer health and beauty products. The company serves customers under the 36.6, Romir, and Gorzdrav brands. Public Joint-Stock Company Pharmacy Chain 36.6 was founded in 1991 and is based in Moscow, Russia.
